Can stress cause depression?

World Journal of Biological Psychiatry

Volumn 6, Issue SUPPL. 2, 2005, Pages 5-22

  van Praag, Herman M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anxiety aggression driven depression; Cortisol; CRH; Serotonin; Stress

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 5 HYDROXYINDOLEACETIC ACID; AMINOGLUTETHIMIDE; ANTIDEPRESSANT AGENT; ARGIPRESSIN; CORTICOSTEROID RECEPTOR; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MONOAMINE OXIDASE INHIBITOR; NEUROHORMONE; NORADRENALIN UPTAKE INHIBITOR; PRASTERONE; PRASTERONE SULFATE; PYRAZOLOPYRIMIDINE DERIVATIVE; RU 4868; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGGRESSION; ANXIETY DISORDER; BRAIN DISEASE; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG PENETRATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENTAL DISEASE; MENTAL STRESS; NEUROBIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PERSONALITY; PSYCHOLOGICAL ASPECT; REVIEW; SEROTONIN METABOLISM; SEROTONINERGIC SYSTEM; SIDE EFFECT; STEROIDOGENESIS; TREATMENT PLANNING;

ADRENOCORTICOTROPIC HORMONE; AGGRESSION; ANIMALS; ANXIETY; AROUSAL; BRAIN; BRAIN MAPPING; CORTICOTROPIN-RELEASING HORMONE; DEPRESSIVE DISORDER; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; SEROTONIN; STRESS, PSYCHOLOGICAL;

EID: 23844542126     PISSN: 15622975     EISSN: None     Source Type: Journal    
DOI: 10.1080/15622970510030018     Document Type: Review

References (153)

1. 11C]5-hydroxytrypyonphan in major depression: a position emission tomography study on patients and healthy volunteers. Acta Psychiatr Scand 83:449-455.
2. Agren H, Reibring L. 1994. PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiatry 27:2-6.
3. Ansseau M. 1997. Hormonal disturbances in depression. In: Honig A, Van Praag HM, editors. Depression. Neurobiological, psychopathological and therapeutic advances. Chichester: John Wiley.
4. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. 1999. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1-12.
5. Arborelius L, Skelton KH, Thrivikraman KV, Plotsky PM, Schulz DW, Owens MJ. 2000. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: Behavioral, endocrine and neurochemical effects in the rat. J Pharmacol Exp Ther 294:588-597.
6. Asberg M, Thorén P, Träskman L, Bertilsson L, Ringbergen V. 1976. Serotonin depression: A biochemical subgroup within the affective disorders? Science 191:478-480.
7. 2A receptor binding index in deliberate self-harm patients. Eur J Nucl Med 28:175-182.
8. Baker DG, West SA, Nicholson WE, Ekhator NN, Kasckow JW, Hill KK, Bruce AB, Orth DN, Geracioti TD. 1999. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 156:585-588.
9. Banki CM, Bissette G, Arato M, O'Connor L, Nemeroff CB. 1987. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 144:873-877.
10. Barrett-Connor E, Von Mühlen D, Laughlin GA, Kripke A. 1999. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: The Rancho Bernado study. J Am Geriatr Soc 47:685-691.
11. Basso AM, Spina M, River J, Vale W, Koob GF. 1999. Corticotropin-releasing factor antagonist attenuates the anxiogenic-like effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology 145:21-30.
12. Benkelfat C, Ellenbogen M, Dean P, Palmour R, Young S. 1994. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psychiatry 51:687-697.
13. Benkelfat C, Young SN, Leyton M, Diksie M. 2002. Impulsivity: Serotonergic mechanisms. Int J Neuropsychopharmacol 5(Suppl I):S13.
14. Beverley E, Murphy P. 1997. Antiglucocorticoid therapies in major depression: A review. Psychoneuroendocrinology 22:S125-132.
15. Bhagwagar Z, Whale R, Cowen PJ. 2002. State and trait abnormalities in serotonin function in major depression. Br J Psychiatry 180:24-28.
16. Blier P, De Montigny C. 1994. Current advances and trends in the treatment of depression. Trends Pharm Sci 15:220-226.
17. Board F, Persky H, Hamburg DA. 1956. Psychological stress and endocrine functions. Psychosom Med 18:324-333.
18. Borsini F, Brambilla A, Grippa N, Pitsikas N. 1999. Behavioral effects of Flibanserin (BIMT 17). Pharmacol Biochem Behav 64:137-146.
19. Bremner JD, Randall P, Vermetten E, Staib L, Bronen RA, Mazure C, Capelli S, McCarthy G, Innis RB, Charney DS. 1997. Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse: A preliminary report. Biol Psychiatry 41:23-32.
20. Brody CL, Haaga DA, Kirk L, Solomon A. 1999. Experiences of anger in people who have recovered from depression and never-depressed people. J Nerv Ment Dis 187:400-405.
21. 2C receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl] carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem 43:1123-1134.
22. Carroll BJ. 1982. The dexamethasone suppression test for melancholia. Br J Psychiatry 140:292-304.
23. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R. 2003. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386-389.
24. Catalán R, Gallart JM, Castellanos JM, Galard R. 1998. Plasma corticotropin-releasing factor in depressive disorders. Biol Psychiatry 44:15-20.
25. Chalmers DT, Lovenberg TW, Grigoriadis DE, Behan DP, De Souza EB. 1996. Corticotrophin-releasing factor receptors: From molecular biology to drug design. Trends Pharmacol Sci 17:166-172.
26. Charney DS. 2004. Psychobiological mechanisms of resilience and vulnerability: Implications for successful adaptation to extreme stress. Am J Psychiatry 161:195-216.
27. 11C]Methyl-L-tryptophan PET maps brain serotonin synthesis and kynurenine pathway metabolism. J Cereb Blood Flow Metab 20:2-9.
28. Coccaro EF. 1992. Impulsive aggression and central serotonergic system unction in humans; an example of a dimensional brain-behavior relationship. Int Clin Psychopharmacol 7:3-12.
29. 2A receptor binding. Neuropsychopharmacology 16:211-216.
30. Cole MA, Kim PJ, Kalman BA, Spencer RL. 2000. Dexamethasone suppression of corticosteroid secretion: Evaluation of the site of action by receptor measures and functional studies. Psychoneuroendocrinology 25:151-167.
31. Contarino A, Dellu F, Koob GF, Smith GW, Lee KF, Vale W, Gold LH. 1999. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res 835:1-9.
32. Corrêa H, Duval F, Mokrani M-C, Bailey P, Trémeau F, Staner L, Diep T-S, Hodé Y, Crocq M-A, Macher J-P. 2000. Prolactin response to D-fenfluramine and suicidal behavior in depressed patients. Psychiatr Res 93:189-199.
33. Cowen PJ, Wood DJ. 1991. Biological markers of depression. Psychol Med 21:831-836.
34. Cowen PJ, Charig EM, Fraser S, Elliot JM. 1987. Platelet 5HT receptor binding during depressive illness and tricyclic antidepressant treatment. J Affect Disord 13:45-50.
35. Crayton JW, Joshi I, Gulati A, Arora RC, Wolf WA. 1996. Effect of corticosterone on serotonin and catecholamine receptors and uptake sites in rat frontal cortex. Brain Res 728:260-262.
36. Davis S, Heal DJ, Stanfort SC. 1995. Long-lasting effects of and acute stress on the neurochemistry and function of 5-hydroxytryptaminergic neurones in the mouse brain. Psychopharmacology 118:267-272.
37. 1A agonists in anxiety and depression. J Psychopharmacol 7:283-289.
38. Deakin JFW, Pennell I, Upadhyaya AJ, Lofthouse R. 1990. A neuroendocrine study of 5-HT function in depression: Evidence for biological mechanisms of endogenous and psychosocial causation. Psychopharmacology 101:85-92.
39. De Bellis MD, Baum AS, Birmaher B, Keshavan MS, Eccard CH, Boring AM, Jenkins FJ, Ryan ND. 1999. Developmental traumatology part I: Biological stress systems. Biol Psychiatry 45:1259-1270.
40. De Kloet ER. 1991. Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol 12:95-164.
41. De Kloet ER, Reul JM. 1987. Feedback action and tonic influence of corticosteroids on brain function: A concept arising from the heterogeneity of brain receptor systems. Psychoneuroendocrinology 12:83-105.
42. Delgado P, Moreno F. 2000. Role of norepinephrine in depression. J Clin Psychiatry 61(Suppl):5-12.
43. Delgado PL, Charney DS, Price LH, Landis H, Heninger GR. 1989. Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects. Life Sci 45:2323-2332.
44. De Souza EB. 1995. Corticotropin-releasing factor receptors: Physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology 20:789-819.
45. D'Haenen H, Bossuyt A, Mertens J, Bossuyt-Piron C, Gijsemans M, Kaufman L. 1992. SPECT imaging of serotonin2 receptors in depression. Psychiatr Res Neuroimaging 45:227-237.
46. Diksic M, Nagahiro S, Sourkes TL, Yamamoto YL. 1990. A new method to measure brain serotonin synthesis in vivo, I: Theory and basic data for a biological model. J Cereb Blood Flow Metab 10:1-12.
47. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, Huang Y, Gautier C, Mathis C. 1999. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 46:1375-1387.
48. Eaves M, Britton KT, Rivier J, Vale W, Koob GF. 1985. Effects of corticotropin releasing factor on locomotor activity in hypophysectomized rats. Peptides 6:923-926.
49. 2a receptor binding after chronic corticosterone associated with a behavioural indication of depression but not anxiety. Psychoneuroendocrinology 22:477-491.
50. Florey JD, Mann JJ, Manuck SB, Muldoon MF. 1998. Recovery from major depression is not associated with normalisation of serotonergic function. Biol Psychiatry 43:320-326.
51. Geracioti TD, Loosen PT, Orth DN. 1997. Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry 42:166-174.
52. Germine M, Goddard AW, Woods CW, Charney DS, Heninger GR. 1992. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry 32:457-461.
53. Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese IR, Kellner CH, Nieman LK, Post RM, Pickar D, Gallucci W, Avgerinos P, Paul S, Oldfield EH, Cutler GB, Chrousos GP. 1986. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease: Pathophysiologic and diagnostic implications. New Engl J Med 314:1329-1335.
54. Gross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L, Santarelli L, Beck S, Hen R. 2002. Serotonin1A receptor acts during development to establish normal anxiety-like behavior in the adult. Nature 416:396-400.
55. Heinrichs SC, Menzaghi F, Merlo Pich E, Britton KT, Koob GF. 1995. The role of CRF in behavioral aspects of stress. Ann NY Acad Sci 771:92-104.
56. Heinrichs SC, Lapsansky J, Lovenberg TW, De Souza EB, Chalmers DT. 1997. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behaviour. Regul Peptides 71:15-21.
57. Holsboer F. 1999. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. Psychiatr Res 33:181-214.
58. Holsboer F. 2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477-501.
59. Holsboer F. 2001. Stress, hypercortisolism and corticosteroid receptors in depression: Implications for therapy. J Affect Disord 62:77-91.
60. Holsboer-Trachsler E, Stohler R, Hatzinger M. 1991. Repeated administration of the combined dexamethasone human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatr Res 38:163-171.
61. 2 sites in cortex and amygdale. Brain Res 614:37-44.
62. Hucks D, Lowther S, Rufus Crompton M, Katona CLE, Horton RW. 1997. Corticotropin-releasing factor binding sites in cortex of depressed suicides. Psychopharmacology 134:174-178.
63. Joëls M, De Kloet E. 1994. Mineralocorticoid and glucocorticoid receptors in the brain. Implications for ion permeability and transmitter systems. Prog Neurobiol 43:1-36.
64. Kimonides VG, Khatibi NH, Svendsen CN, Sofroniew MV, Herbert J. 1998. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DH-EAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc Natl Acad Sci USA 95:1852-1857.
65. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F, Hermanson O, Rosenfeld MG, Spiess J. 2000. Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24:415-419.
66. Klaassen T, Riedel WJ, Van Someren A, Deutz NEP, Honig A, Van Praag HM. 1999a. Mood effects of 24-hour tryptophan depletion in healthy first-degree relatives of patients with affective disorders. Biol Psychiatry 46:489-497.
67. Klaassen T, Riedel WJ, Deutz NEP, Van Someren A, Van Praag HM. 1999b. Specificity of the tryptophan depletion method. Psychopharmacology 141:279-286.
68. Koob GF, Heinrichs SC, Pich EM, Menzaghi F, Baldwin H, Miczek K, Britton KT. 1993. The role of corticotropin-releasing factor in behavioural responses to stress. In: De Souza EB, Nemeroff CB, editors. Corticotropin-releasing factor: Basic and clinical studies of a neuropeptide. Chichester: John Wiley & Sons.
69. Krishnan KRR, Doraiswamy PM, Lurie SN, Figiel GS, Husain MM, Boyko OB, Ellinwood EH, Nemeroff CB. 1991. Pituitary size in depression. J Clin Endocrinol Metab 72:256-259.
70. 1a receptor responsivity in unipolar depression: Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatry 28:620-628.
71. 11C]Metyl-L-Tryptophan trapping in impulsive subjects with borderline personality disorder. Am J Psychiatry 158:775-782.
72. Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimon R, Goodwin FK. 1983. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from non impulsive violent behaviour. Life Sci 33:2609-2619.
73. Maes M, Meltzer H. 1995. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The fourth generation of progress. New York: Raven Press.
74. Maes M, Jacobs M.P, Suy E, Minner B, Leclercq C, Christiaens F, Raus J. 1990. Suppressant effects of dexamethasone on the availability of plasma 1-tryptophan and tyrosin in healthy controls and in depressed patients. Acta Psychiatr Scand 81:19-23.
75. Malison RT, Anand A, Pelton GH, Kirwin P, Carpenter L, McDougle CJ, Heninger GR, Price LH. 1999. Limited efficacy of ketoconazole in treatment-refractory major depression. J Clin Psychopharmacol 19:466-470.
76. Mayorga A, Dalvi A, Page M, Zimov-Levinson S, Hen R, Lucki I. 2001. Antidepressant-like behavioral effects in 5-hydroxytryptamine1A and 5-hydroxytryptamine1B receptor mutant mice. J Pharmacol Exp Ther 298:1101-1107.
77. McKittrick CR, Blanchard DC, Blanchard RJ, McEwen BS, Sakai RR. 1995. Serotonin receptor binding in a colony model of chronic social stress. Biol Psychiatry 37:383-393.
78. McQuade R, Young AH. 2000. Future therapeutic targets in mood disorders: The glucocorticoid receptor. Br J Psychiatry 177:390-395.
79. 1a receptor mRNA in rat dentate gyrus. Eur J Pharmacol Mol Pharm Sect 266:255-261.
80. 2 receptors in depression: An [18F]Setoperone PET imaging study. Am J Psychiatry 156:1029-1034.
81. Mignot E, Seffano A, Laude D, Elghozi JL, Dedek J, Scatton B. 1985. Measurement of 5-HIAA levels in ventricular CSF (by LCEC) and in striatum (by in vivo voltametry) during pharmacological modification of serotonin metabolism in the rat. J Neural Transm 62:117-124.
82. Modell S, Yassouridis A, Huber J, Holsboer F. 1997. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 65:216-222.
83. Modell S, Lauer CJ, Schreiber M, Huber J, Krieg JC, Holsboer F. 1998. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology 18:253-262.
84. Moja E, Cipolla P, Castoldi D, Tofanetti O. 1989. Dose-response decrease in plasma tryptophan and in brain tryptophan and serotonin after tryptophan-free amino acid mixtures in rats. Life Sci 44:971-976.
85. Murphy BEP. 1997. Antiglucocorticoid therapies in major depression: A review. Psychoneuroendocrinology 22:S125-132.
86. Murphy BEP, Dhar V, Ghadirian AM, Chouinard G, Keller R. 1991. Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol 11:121-126.
87. Nemeroff CB. 1996. The corticotropin-releasing factor hypothesis of depression: New findings and directions. Mol Psychiatry 1:336-342.
88. Nemeroff CB, Widerlöv E, Bissette G, Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W. 1984. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226:1342-1344.
89. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. 1988. Reduced corticotropin-releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 45:577-579.
90. Newman ME, Shapira B, Lerer B. 1998. Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: A critical review. Int J Neuropsychopharmacology 1:49-69.
91. Owens MJ, Nemeroff CB. 1991. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43:425-473.
92. Owens MJ, Nemeroff CB. 1999. Corticotropin-releasing factor antagonists. CNS Drugs 12:85-92.
93. Pandey GN, Pandey SC, Janicak PG, Marks RC, Davis JM. 1990. Platelet serotonin receptor binding sites in depression and suicide. Biol Psychiatry 28:215-222.
94. Parks C, Robinson P, Sibille E, Shenk Th, Toth M.. 1998. Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci USA 95:10734-10739.
95. Patchev VK, Shoaib M, Holsboer F, Almeida OF. 1994. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience 62:265-271.
96. Porter R, McAllister-Williams RH, Lunn B, Young A. 1998. 5-Hydroxytryptamine receptor function in man is reduced by acute administration of hydrocortisone. Psychopharmacology 139:243-250.
97. Purba JS, Hoogendijk WJG, Hofman MA, Swaab DF. 1996. Increased number of vasopressin neurons in the paraventricular nucleus of the human hypothalamus in depression. Arch Gen Psychiatry 53:137-143.
98. Raadsheer FC, Hoogendijk WJG, Hofman MA, Swaab DF. 1994. Increased numbers of corticotropin-releasing hormone neurons in the hypothalamic-paraventricular nucleus of depressed patients. Clin Neuroendocrinol 60:436-444.
99. Raadsheer FC, Van Heerikhuize JJ, Lucassen PJ, Hoogendijk WJ, Tilders FJ, Swaab DF. 1995. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am J Psychiatry 152: 1372-1376.
100. Ravaris CL, Sateia MJ, Beroza KW, Noordsy DL. 1988. Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman. Arch Gen Psychiatry 45: 966-967.
101. 1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur J Pharmacol 318:213-230.
102. Reul JM, Stec I, Soder M, Holsboer F. 1993. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 133:312-320.
103. Riedel WJ, Klaassen T, Griez E, Honig A, Menheere PPCA, Van Praag HM. 2002. Dissociable hormonal, cognitive and mood responses to neuroendocrine challenge: Evidence for receptor-specific serotonergic dysregulation in depressed mood. Neuropsychopharmacology 26:358-367.
104. Sachar EJ, Hellman L, Roffwarg HP, Halpern FS, Fukushima DK, Gallagher TF. 1973. Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Arch Gen Psychiatry 28:19-24.
105. 1B receptors. Science 265:1875-1878.
106. 11C]WAY-100635. Effects of depression and antidepressant treatment. Arch Gen Psychiatry 57:174-180.
107. Schreiber W, Lauer CJ, Krumrey K, Holsboer F, Krieg JC. 1996. Dysregulation of the hypothalamic-pituitary-adrenocortical system in panic disorder. Neuropsychopharmacology 15:7-15.
108. Scott LV, Thakore J, Burnett F, Dinan TG. 1999. A preliminary study of dexamethasone treatment on pituitary-adrenal responsivity in major depression. Hum Psychopharmacol Clin Exp 14:587-591.
109. Seckl JR, Fink G. 1992. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 55:621-626.
110. Sibille E, Sarnyai Z, Benjamin D, Gal J, Baker H, Toth M. 1997. Antisense inhibition of 5-hydroxytryptamine 2A receptor induces an antidepressant effect in mice. J Pharmacol Exp Ther 52:1056-1063.
111. Souza EB, De Loon GR. 1986. Brain serotonin and catecholamine responses to repeated stress in rats. Brain Res 367:77-86.
112. Stanley M, Traskman L, Dorovine K. 1985. Correlation between aminergic metabolites simultaneously obtained from human CSF and brain. Life Sci 37:1279-1286.
113. Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW. 1994. Overproduction of corticotropin-releasing factor in transgenic mice: A genetic model of anxiogenic behaviour. J Neurosci 14:2579-2584.
114. Thakore JH, Dinan TG. 1994. d-Fenfluramine-induced prolactin release in depression: The acute effects of ketoconazole. J Seroton Res 3:7-213.
115. Träskman-Bendz L, Åsberg M, Bertilsson L, Thorén P. 1984. CSF monoamine metabolites of depressed patients during illness and after recovery. Acta Psychiatr Scand 69:333-342.
116. Van Praag HM. 1969. Depressie en de stofwisseling van 5-hydroxytryptamine (Depression and the metabolism of 5-hydroxytryptamine). Ned Tijdschr Geneesk (Dutch Med J) 113:2245-2247.
117. Van Praag HM. 1977. Significance of biochemical parameters in the diagnosis, treatment and prevention of depressive disorders. Biol Psychiatry 12:101-131.
118. Van Praag HM. 1988. Serotonergic mechanisms and suicidal behaviour. Psychiatr Psychobiol 3:335-346.
119. Van Praag HM. 1992a. Make believes in psychiatry or the perils of progress. New York: Brunner Mazel.
120. Van Praag HM. 1992b. About the centrality of mood lowering in mood disorders. Eur Neuropsychopharmacol 2:393-404.
121. Van Praag HM. 1996a. Serotonin-related, anxiety/aggression-driven, stressor-pecipitated depression. A psychobiological hypothesis. Eur Psychiatry 11:57-67.
122. Van Praag HM. 1996b. Faulty cortisol/serotonin interplay. Psychopathological and biological characterisation of a new hypothetical depression subtype (SeCa depression). Psychiatr Res 65:143-157.
123. Van Praag HM. 1997a. Demoralization and melancholy: Concerning the biological interface between traumatic life experiences and depression. In: Honig A, Van Praag HM, editors. Depression: Neurobiological, psychopathological and therapeutic advances. Chichester: John Wiley & Sons Ltd.
124. Van Praag HM. 1997b. Over the mainstream: Diagnostic requirements for biological psychiatric research. Psychiatr Res 72:201-212.
125. Van Praag HM. 2000. Nosologomania, a disorder of psychiatry. World J Biol Psychiatry 1:151-158.
126. Van Praag HM. 2001a. Historical and contemporary notes on the treatment of depression, or, How classification shaped therapeutic approaches. In: Den Boer JA, Westenberg HGM, editors. Antidepressants: selectivity or multiplicity?. Amsterdam: Benecke.
127. Van Praag HM. 2001b. Anxiety/aggression-driven depression. A paradigm of functionalization and verticalization of psychiatric diagnosis. Prog Neuro-Psychopharmacol Biol Psychiatry 25:893-924.
128. Van Praag HM, Korf J. 1971. Endogenous depressions with and without disturbances in the 5-hydroxytryptamine metabolism: A biochemical classification? Psychopharmacology 19:148-152.
129. Van Praag HM, Korf J, Puite J. 1970. 5-Hydroxindoleacetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid. Nature 225:1259-1260.
130. Van Praag HM, De Haan S. 1980a. Central serotonin deficiency. A factor which increases depression vulnerability? Acta Psychiatr Scand 61:89-95.
131. Van Praag HM, De Haan S. 1980b. Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatr Res 3:75-83.
132. Van Praag HM, Kahn R, Asnis GM, Wetzler S, Brown S, Bleich A, Korn M. 1987. Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. J Affect Disord 13:1-8.
133. Van Praag HM, De Kloet F, Van Os J. 2004. Stress, the brain and depression. Cambridge: Cambridge University Press.
134. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C, Rivier J, Sawchenko PE, Vale W. 1995. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378:287-292.
135. Virkkunen M, Rawlings R, Tokola R, Poland RE, Guidotti A, Nemeroff C, Bissette G, Kalogeras K, Karonen SL, Linnoila M. 1994. CSF biochemistries, glucose metabolism and diurnal activity rhythms in alcoholic violent offenders, fire setters and healthy volunteers. Arch Gen Psychiatry 51:20-27.
136. Von Bardeleben U, Holsboer F. 1989. Cortisol response to a combined dexamethasone-hCRH challenge in patients with depression. J Neuroendocrinol 1:485-488.
137. Weiss JM, Goodman PA, Losito BG, Corrigan S, Charry JM, Bailey WH. 1981. Behavioral depression produced by an uncontrollable stressor: Relationship to norepinephrine, dopamine, and serotonin levels in various regions of rat brain. Brain Res Rev 3:167-205.
138. 1D receptors in melancholic depression. Br J Psychiatry 178:454-457.
139. Whalley LJ, Borthwick N, Copolov D, Dick H, Christie JE, Fink G. 1986. Glucocorticoid receptors and depression. Br Med J 292:859-861.
140. Williams WA, Shoaf SE, Hommer D, Rawlings R, Linnoila M. 1999. Effects of acute tryptophan depletion on plasma and cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in normal volunteers. J Neurochem 72:1641-1647.
141. Wolkowitz OM, Reus VI, Weingartner H, Thompson K, Breier A, Doran A, Rubinow D, Pickar D. 1999a. Treatment of depression with antiglucocorticoid drugs. Psychosom Med 61:698-711.
142. Wolkowitz OM, Reus VI, Weingartner H, Thompson K, Breier A, Doran A, Rubinow D, Pickar D, Chan T, Knutson B. 1999b. Antiglucocorticoid treatment of depression: Double-blind ketoconazole. Biol Psychiatry 45:1070-1074.
143. Wong M-L, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, Karp B, McCutcheon LE, Geracioti TD, DeBellis MD, Rice KC, Goldstein DS, Veldhuis JD, Chrousos GP, Oldfield EH, McCann SM, Gold PW 2000. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: Relation to hypercorticoslism and corticotropin-releasing hormone. Proc Natl Acad Sci USA 97:325-330.
144. 2 receptor antagonists on the anti-immobility effects of imipramine in the forced swimming test with mice. Eur J Pharmacol 427:221-225.
145. 2a receptor-mediated head shakes in rats. Psychopharmacology 119:9-14.
146. Yatham LN, Liddle PF, Dennie JL, Shiah I, Adam MJ, Lane CJ, Lam RW, Ruth ThJ. 1999. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment. Arch Gen Psychiatry 56:705-711.
147. Yatham LN, Liddle PF, Shiah I-S, Scarrow G, Lam RW, Adam MJ, Zis AP, Ruth TJ. 2000. Brain serotonin2 receptors in major depression. A positron emission tomography study. Arch Gen Psychiatry 57:850-858.
148. Young S, Smith S, Pihl R, Ervin F. 1985. Tryptophan depletion cases a rapid lowering of mood in normal males. Psychopharmacology (Berlin) 87:173-177.
149. Young EA, Haskett RF, Murphy-Weinberg V, Watson SJ, Akil H. 1991. Loss of glucocorticoid fast feedback in depression. Arch Gen Psychiatry 48:693-699.
150. 1a presynaptic function in the mouse. Psychopharmacology 114:360-364.
151. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H. 2000. Hormonal evidence for altered responsiveness to social stress in major depression. Neuropsychopharmacology 23: 411-418.
152. Zobel AW, Yassouridis A, Frieboes RM, Holsboer F. 1999. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry 156:949-951.
153. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F. 2000. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171-181.